中性粒细胞明胶酶相关脂质运载蛋白升高与COVID-19肾损伤严重程度及不良预后相关
这项前瞻性队列研究纳入444例连续SARS-CoV-2感染患者,入院时检测尿液生物标志物。发现入院uNGAL水平与AKI诊断和分期相关,>150 ng/ml诊断AKI 2-3期的特异性80%、敏感性75%,且低uNGAL对排除AKI 2-3期和透析需求有高阴性预测值。uNGAL还与延长的AKI、透析、休克、延长住院和院内死亡定量相关。
要点
- 入院uNGAL水平与AKI诊断和分期相关,>150 ng/ml诊断AKI 2-3期特异性80%、敏感性75%。
- uNGAL每增加1个SD,透析风险独立增加近4倍(OR 3.59,95%CI 1.83-7.45)。
- 低uNGAL水平可排除AKI 2-3期(NPV 0.95)和透析需求(NPV 0.98)。
核心结论
- 在COVID-19患者中,uNGAL水平与组织病理学损伤(ATI)、肾功能丧失(AKI)和患者结局严重程度定量相关。
研究设计与样本
- 前瞻性队列观察性研究,纳入哥伦比亚大学急诊科2020年3月至4月连续444例SARS-CoV-2感染患者。
- 入院时同时采集尿液和血液(中位时间第0天,四分位距0-2天),用ELISA和新型试纸条分析尿液生物标志物。
- 肾活检检测生物标志物RNA和急性肾小管损伤(ATI)组织病理学评分。
主要发现
- 入院uNGAL水平与AKI诊断相关(267±301 vs. 96±139 ng/ml,P<0.0001)及分期。
- uNGAL>150 ng/ml诊断AKI 2-3期的特异性80%、敏感性75%。
- 入院uNGAL水平与延长的AKI、透析、休克、延长住院和院内死亡定量相关,即使入院SCr未升高。
- 透析风险随uNGAL每SD增加近4倍,独立于基线SCr、合并症和蛋白尿(OR 3.59,95%CI 1.83-7.45,P<0.001)。
- 低uNGAL水平排除AKI 2-3期(NPV 0.95,95%CI 0.92-0.97)和透析需求(NPV 0.98,95%CI 0.96-0.99)。
关键数值与推荐
- uNGAL>150 ng/ml诊断AKI 2-3期:敏感性75%,特异性80%。
- 低uNGAL排除AKI 2-3期:阴性预测值0.95(95%CI 0.92-0.97)。
- 低uNGAL排除透析需求:阴性预测值0.98(95%CI 0.96-0.99)。
- uNGAL每SD与透析风险:OR 3.59(95%CI 1.83-7.45),P<0.001。
临床怎么用
- 入院uNGAL可辅助识别COVID-19患者中AKI 2-3期高风险者,即使SCr未升高。
- 低uNGAL水平有助于排除进展至AKI 2-3期或需要透析的低风险患者。
- 蛋白尿和uKIM-1虽与肾小管损伤相关,但均不能诊断AKI分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Loss of kidney function is a common feature of COVID-19 infection, but serum creatinine (SCr) is not a sensitive or specific marker of kidney injury. We tested whether molecular biomarkers of tubular injury measured at hospital admission were associated with acute kidney injury (AKI) in those with COVID-19 infection. METHODS: This is a prospective cohort observational study consisting of 444 consecutive patients with SARS-CoV-2 enrolled in the Columbia University emergency department (ED) at the peak of the pandemic in New York (March 2020-April 2020). Urine and blood were collected simultaneously at hospital admission (median time: day 0, interquartile range: 0-2 days), and urine biomarkers were analyzed by enzyme-linked immunosorbent assay (ELISA) and a novel dipstick. Kidney biopsies were probed for biomarker RNA and for histopathologic acute tubular injury (ATI) scores. RESULTS: Admission urinary neutrophil gelatinase-associated lipocalin (uNGAL) level was associated with AKI diagnosis (267 ± 301 vs. 96 ± 139 ng/ml, P < 0.0001) and staging; uNGAL levels >150 ng/ml had 80% specificity and 75% sensitivity to diagnose AKI stages 2 to 3. Admission uNGAL level quantitatively associated with prolonged AKI, dialysis, shock, prolonged hospitalization, and in-hospital death, even when admission SCr level was not elevated. The risk of dialysis increased almost 4-fold per SD of uNGAL independently of baseline SCr, comorbidities, and proteinuria (odds ratio [OR] [95% CI]: 3.59 [1.83-7.45], P < 0.001). In the kidneys of those with COVID-19, NGAL mRNA expression broadened in parallel with severe histopathologic injury (ATI). Conversely, low uNGAL levels at admission ruled out stages 2 to 3 AKI (negative predictive value: 0.95, 95% CI: 0.92-0.97) and the need for dialysis (negative predictive value: 0.98, 95% CI: 0.96-0.99). Although proteinuria and urinary (u)KIM-1 were implicated in tubular injury, neither was diagnostic of AKI stages. CONCLUSION: In the patients with COVID-19, uNGAL level was quantitatively associated with histopathologic injury (ATI), loss of kidney function (AKI), and severity of patient outcomes.
引用
- Xu K, Shang N, Levitman A, et al. Elevated Neutrophil Gelatinase-Associated Lipocalin Is Associated With the Severity of Kidney Injury and Poor Prognosis of Patients With COVID-19. Kidney Int Rep. 2021. PMID: 34642645. doi:10.1016/j.ekir.2021.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。